IRWD Stock - Ironwood Pharmaceuticals, Inc.
Unlock GoAI Insights for IRWD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $351.41M | $442.74M | $410.60M | $413.75M | $389.52M |
| Gross Profit | $343.86M | $436.59M | $409.18M | $343.35M | $386.39M |
| Gross Margin | 97.9% | 98.6% | 99.7% | 83.0% | 99.2% |
| Operating Income | $93.12M | $-945,430,000 | $250.34M | $232.26M | $142.94M |
| Net Income | $880,000 | $-1,002,239,000 | $175.06M | $528.45M | $106.18M |
| Net Margin | 0.3% | -226.4% | 42.6% | 127.7% | 27.3% |
| EPS | $0.01 | $-6.45 | $1.13 | $3.26 | $0.67 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Visit WebsiteEarnings History & Surprises
IRWDEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.02 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.09 | $0.24 | +166.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.02 | $0.14 | +800.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.05 | $-0.14 | -180.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.10 | $0.02 | -80.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.08 | $0.02 | -75.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.15 | $-0.01 | -103.6% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.18 | $-0.02 | -111.1% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $0.21 | $-0.01 | -104.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.16 | $0.09 | -43.8% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.25 | $0.31 | +24.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.24 | $0.25 | +4.2% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $0.27 | $0.27 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $0.27 | $0.28 | +3.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.30 | $0.21 | -30.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $0.26 | $0.21 | -19.2% | ✗ MISS |
Q1 2022 | Feb 17, 2022 | $0.35 | $0.27 | -22.9% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $0.31 | $0.33 | +6.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.23 | $0.34 | +47.8% | ✓ BEAT |
Latest News
Frequently Asked Questions about IRWD
What is IRWD's current stock price?
What is the analyst price target for IRWD?
What sector is Ironwood Pharmaceuticals, Inc. in?
What is IRWD's market cap?
Does IRWD pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IRWD for comparison